Fifth Third Bancorp reduced its position in CONMED Corporation (NYSE:CNMD – Free Report) by 25.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,158 shares of the company’s stock after selling 17,502 shares during the quarter. Fifth Third Bancorp owned approximately 0.17% of CONMED worth $2,319,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new position in CONMED in the 2nd quarter valued at approximately $157,783,000. Dimensional Fund Advisors LP increased its position in shares of CONMED by 6.1% during the first quarter. Dimensional Fund Advisors LP now owns 1,392,920 shares of the company’s stock worth $49,250,000 after acquiring an additional 80,116 shares during the period. Bank of America Corp DE purchased a new stake in shares of CONMED during the second quarter worth $43,904,000. Paradigm Capital Management Inc. NY acquired a new stake in shares of CONMED in the second quarter valued at $17,617,000. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of CONMED by 217.6% in the first quarter. Arrowstreet Capital Limited Partnership now owns 419,092 shares of the company’s stock valued at $14,819,000 after acquiring an additional 287,150 shares in the last quarter.
CONMED Stock Up 0.4%
CONMED stock opened at $46.58 on Friday. The company has a market capitalization of $1.39 billion, a P/E ratio of 19.25, a PEG ratio of 2.16 and a beta of 0.90. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.70 and a current ratio of 1.49. CONMED Corporation has a fifty-two week low of $31.44 and a fifty-two week high of $54.80. The stock has a 50-day simple moving average of $47.22 and a 200-day simple moving average of $42.15.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on CNMD. Weiss Ratings downgraded CONMED from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday. Zacks Research upgraded CONMED from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Piper Sandler reaffirmed a “neutral” rating and issued a $45.00 target price (up from $39.00) on shares of CONMED in a report on Thursday, July 30th. JPMorgan Chase & Co. lifted their price target on shares of CONMED from $45.00 to $50.00 and gave the stock a “neutral” rating in a research note on Thursday, October 29th. Finally, Wells Fargo & Company boosted their price target on shares of CONMED from $46.00 to $49.00 and gave the stock an “equal weight” rating in a report on Thursday, October 29th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CONMED presently has a consensus rating of “Reduce” and a consensus price target of $44.00.
Read Our Latest Report on CNMD
About CONMED
CONMED Corporation is a medical technology company that develops and markets devices and equipment for orthopedic and general surgery. Its products support minimally invasive procedures and include arthroscopy systems, powered surgical instruments, electrosurgical equipment, and endoscopic technologies. The company was founded in 1970 and serves hospitals, surgery centers, and other healthcare providers. Its products are sold in the United States and internationally.
Featured Articles
- Five stocks we like better than CONMED
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding CNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CONMED Corporation (NYSE:CNMD – Free Report).
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.
